Table 2.

Validation study patient characteristics

		Non-Stroke		Stroke		p (Fisher’s Test)
		n	%	n	%
Age and gender	N	34	–	139	–	NA
	Gender: male	19	55.9	90	64.7	0.428
	Median age [IQR]	63.5 [53.8–68.0]	–	68.0 [57.0–76.0]	–	0.055✞
Risk factors for ischaemic stroke	Hypertension, % (n)	13	38.2	57	41.0	0.847
	Atrial fibrillation, % (n)	3	8.8	27	19.4	0.206
	Diabetes (types 1 or 2), % (n)	7	20.6	24	17.3	0.625
	Hyperlipidaemia, % (n)	6	17.6	36	25.9	0.378
	Peripheral vascular disease, % (n)	2	5.9	1	0.7	0.099
	Smoker, % (n)	9	26.5	45	32.4	0.544
	Ex-smoker, % (n)	11	32.4	23	16.5	0.053
	Previous stroke, % (n)	5	14.7	19	13.7	1.000
	Family history, % (n)	4	11.8	22	15.8	0.789
Medication	Recombinant tissue plasminogen activator, % (n)	–	–	39	28.1	NA
	ACE inhibitor, % (n)	8	23.5	32	23.0	1.000
	Alpha blocker, % (n)	0	0.0	1	0.7	1.000
	Anticoagulant, % (n)	2	5.9	8	5.8	1.000
	Antiplatelet, % (n)	14	41.2	51	36.7	0.694
	ARB, % (n)	1	2.9	9	6.5	0.689
	Beta blocker, % (n)	10	29.4	35	25.2	0.664
	Blood pressure treatment, % (n)	14	41.2	68	48.9	0.449
	CCB, % (n)	5	14.7	25	18.0	0.803
	Loop diuretic, % (n)	1	2.9	15	10.8	0.202
	Oral hypoglycaemic drugs, % (n)	2	5.9	10	7.2	1.000
	Spironolactone, % (n)	1	2.9	2	1.4	0.484
	Statin, % (n)	16	47.1	60	43.2	0.704
	Thiazide, % (n)	3	8.8	15	10.8	1.000
Stroke status	Median baseline NIHSS [IQR]	1 [0–3]	–	4 [2–7]	–	< 0.0001♦

Demographical data for the full cohort of patients used in the validation study. For dichotomous variables, a Fisher’s exact test was used to assess differences. For continuous variables, an unpaired two-tailed Student’s t test (✞) or Mann Whitney U test (♦) was used

ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, CCB calcium channel blocker, NIHSS National Institutes of Health Stroke Scale